Who mentions $CATX most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $CATX most — 4 mentions in the past 12 months.

When was $CATX first mentioned on Surfaced?

The earliest tracked mention of $CATX in the Surfaced archive was on Oct 22, 2025.

How many voices track $CATX?

2 FinTwit voices have mentioned $CATX 5 times in the past 12 months.

What kind of voices mention $CATX most?

$CATX is mentioned most by Biotech voices on Surfaced.

Last 12mo stats

mentions

voices

$CATX

Perspective Therapeutics Inc

$CATX

Perspective Therapeutics Inc

Past 12mo:5mentions2voices

All voices5 mentions past 12mocalls only

Loading price chart…

About this stock

$CATX, a precision oncology company using alpha-particle therapy for cancer treatment, received mentions from 2 distinct FinTwit voices across 5 posts over a 12-month period from October 2025 to April 2026. Jacob Plieth (@jacobplieth) drove the conversation with 4 mentions, while InvestmentGuru (@investmentguru_) contributed 1 mention. The ticker first appeared in the archive on October 22, 2025, with the most recent discussion occurring on April 5, 2026.

AI-generated from tracked posts · updated Sep 5, 2026

Frequently asked

Related stocks

$BCYCBicycle Therapeutics

$CGONCg Oncology

$ZYMEZymeworks BC

$ARWRArrowhead Pharmaceuticals

Recent mentions

5 mentions

@investmentguru_Apr 5, 2026 · 1:22 PM

Low price- high quality penny stocks 1. $VLN Semiconductor for automotive & AI connectivity. Valens maintains $94M cash with zero debt while targeting $220–300M in revenue by 2029. Cash-to-market-cap ratio is exceptional. Auto + AI data connectivity = two massive tailwinds. 2. $GRAB Southeast Asia’s super app — ride-hailing, food delivery, fintech under one roof. Analysts estimate profits to increase approximately 120% over the next twelve months, with emerging market macro tailwinds building. Cash-heavy, now profitable for the first time. Massive addressable market. 3. $SEER Proteomics technology — next frontier of biotech after genomics. Seer carries zero debt with a cash runway exceeding three years, and revenue growth is projected at 29.28% annually. Early innings of a market that could eclipse genomics in scale. 4. $KULR Thermal management for batteries, EVs, 5G, and defense. Analysts upgraded KULR to Strong Buy with a 1-year price target of $5.00 — implying ~290% upside — after the company reported 44% year-over-year revenue growth in Q4 2024. Picks-and-shovels for the battery economy. 5. $CRNT Wireless transport infrastructure — 5G backhaul globally. Ceragon generates $363M in revenue with a market cap of ~$200M, maintains more cash than debt, and recently signed a significant contract in Colombia expanding its Latin American managed services footprint. Wildly undervalued relative to revenue. 6. $CATX Precision oncology using alpha-particle therapy — next-gen cancer treatment. Analysts have given CATX a Strong Buy rating with an average price target of $13.56 — implying over 458% upside from current levels. Binary risk, but the science is legitimate. 7. $STIM FDA-cleared TMS therapy for depression. NeuroStar has one of the largest real-world outcomes registries in TMS, spanning thousands of patients with strong reported response/remission rates — giving it a durable commercial edge in mental health. Mental health infrastructure is a decade-long growth market. 8. $VXRT Needle-free oral vaccine platform — highly differentiated delivery tech. Vaxart’s platform could significantly expand the types of immune response achievable through vaccination, with needle-free formats addressing a massive unmet global need. Pre-revenue but cash-backed. One partnership announcement = multiple on the stock. 9. $XPON Lithium iron phosphate batteries for RVs, marine, and off-grid. As demand for clean and portable energy grows, Expion360 has built a steady niche in the outdoor and recreational market — a sector with loyal, repeat buyers. Profitable niche with expanding TAM. 10. $CGTX Alzheimer’s & Lewy body dementia drug development. Cognition Therapeutics is a clinical-stage biotech targeting Alzheimer’s disease and dementia with Lewy bodies — conditions with enormous unmet need — with stock upside potential tied directly to favorable trial data. One FDA catalyst = complete rerating. Not financial advice. Penny stocks carry extreme volatility. Position size small, diversify wide. DYOR.

Open on X

@jacobpliethJan 30, 2026 · 4:47 PM

$CATX off 10% today though

Open on X

@jacobpliethJan 29, 2026 · 3:22 PM

Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia & renal tox. https://t.co/6L2O0c5cOA Good news for $CATX?

Open on X

@jacobpliethOct 24, 2025 · 9:17 AM

@inshatters1 Is that so? $CATX https://t.co/JyvlddpbmU

Open on X

@jacobpliethOct 22, 2025 · 1:24 PM

Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY

Open on X